Skip to main content
Top
Published in:

22-03-2024 | Hydrocephalus | Review

Reflections upon the intrauterine repair of myelomeningocele

Author: Giuseppe Talamonti

Published in: Child's Nervous System | Issue 5/2024

Login to get access

Abstract

The intrauterine repair of myelomeningocele presents certain advantages and has gained widespread acceptance. It significantly reduces the incidence of Chiari-2 anomalies and hydrocephalus, and it is thought to enhance the neurologic outcome. Nevertheless, several issues remain unsettled and there are no negligible disadvantages. After working with patients with myelomeningocele for 30 years, I thought about how we currently treat them. There are ethical, organizational, neurological, obstetrical, and postnatal aspects worth discussing.
Literature
This content is only visible if you are logged in and have the appropriate permissions.
Metadata
Title
Reflections upon the intrauterine repair of myelomeningocele
Author
Giuseppe Talamonti
Publication date
22-03-2024
Publisher
Springer Berlin Heidelberg
Published in
Child's Nervous System / Issue 5/2024
Print ISSN: 0256-7040
Electronic ISSN: 1433-0350
DOI
https://doi.org/10.1007/s00381-024-06365-0

How can your team use biomarkers to improve management of AD? (Link opens in a new window)

Our experts explore using biomarker tests and interpreting results, establishing a shared decision-making approach with patients and caregivers, and applying biomarker testing to guide treatment strategies.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest

How can you integrate PET into your practice? (Link opens in a new window)

1.5 AMA PRA Category 1 Credit(s)™

PET imaging is playing an increasingly critical role in managing AD. Our expert-led program will empower you with practical strategies and real-world case studies to effectively integrate it into clinical practice.

This content is intended for healthcare professionals outside of the UK.

Supported by:
  • Lilly
Developed by: Springer Health+ IME
Register your interest